Galectin Therapeutics Inc.
GALT
$1.38
$0.010.73%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -6.66% | 9.30% | -7.68% | -14.92% | 4.13% |
| Total Depreciation and Amortization | 11.11% | 0.00% | 0.00% | 0.00% | 12.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -174.36% | 77.47% | -47.68% | 377.27% | -72.24% |
| Change in Net Operating Assets | -70.71% | -64.67% | 236.66% | -146.72% | 225.68% |
| Cash from Operations | -49.81% | -2.46% | 31.16% | -157.44% | 38.43% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -100.00% | 0.00% | 0.00% | 0.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -100.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -91.49% | -3.62% | 3.76% | 0.00% | -0.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -916.69% | -28.44% | 197.05% | -139.73% | 121.12% |